Biodesix (BDSX) Projected to Post Quarterly Earnings on Tuesday

Biodesix (NASDAQ:BDSX) is projected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $19.50 million for the quarter. Biodesix has set its FY 2025 guidance at EPS.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The company had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Price Performance

Shares of NASDAQ BDSX opened at $0.38 on Monday. Biodesix has a 1-year low of $0.34 and a 1-year high of $2.04. The business has a 50-day moving average of $0.63 and a 200-day moving average of $1.02. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The company has a market capitalization of $55.46 million, a price-to-earnings ratio of -0.97 and a beta of 1.18.

Insider Activity at Biodesix

In related news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 128,702 shares of company stock valued at $118,406. Insiders own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BDSX shares. Canaccord Genuity Group decreased their target price on Biodesix from $3.50 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, April 29th. William Blair reissued an “outperform” rating on shares of Biodesix in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Biodesix currently has a consensus rating of “Buy” and a consensus target price of $2.83.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.